-+ 0.00%
-+ 0.00%
-+ 0.00%

Vertex to buy Crinetics for $85 per share in cash, valuing deal at $10 billion

PUBT·07/06/2026 20:04:22
Listen to the news
Vertex to buy Crinetics for $85 per share in cash, valuing deal at $10 billion
  • Vertex agreed to buy Crinetics Pharmaceuticals for USD 85 per share in cash, valuing equity at about USD 10 billion.
  • Net purchase price estimated at about USD 8.8 billion, reflecting expected cash acquired.
  • Closing targeted for Q3 2026, subject to regulatory clearances and Crinetics shareholder approval.
  • Vertex plans to fund the deal with cash and debt, supported by USD 4.5 billion in committed bridge financing.
  • Vertex is adding PALSONIFY, an FDA-approved oral acromegaly drug, and Phase 3 CAH candidate atumelnant; combined peak annual revenue seen above USD 5 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crinetics Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607061604BIZWIRE_USPR_____20260706_BW876183) on July 06, 2026, and is solely responsible for the information contained therein.